Contents
- Hero Section – Why This Liraglutide Is the Smart Choice for Your Portfolio
- Problem Agitation – The 4 Critical Pain Points Holding Your Supply Chain Hostage
- Solution Presentation – Global Technology’s Competitive Edge
- Social Proof – Trusted by Industry Leaders Worldwide
- FAQ – All Procurement Queries Answered
- Strong Call‑to‑Action – Secure Your Stock Before Prices Rise
- Customer Reviews – Voices from the Field
- About the Author – Dr. Elena V. Morozova
CAS 820959-17-9 Liraglutide (recombinant): High‑Purity API for Diabetes & Obesity – Free Sample in 48 h
Accelerate your product pipeline with a GMP‑certified, CAS 820959-17-9 Liraglutide (recombinant) that meets FDA, EMA, and CFDA standards. Ideal for pharmaceutical manufacturers, CROs, and biotech startups targeting GLP‑1 therapies.
Get Free Quote in 24 hProblem Agitation – The 4 Critical Pain Points Holding Your Supply Chain Hostage
In 2025‑2026, the global GLP‑1 market surged past USD 12 billion, yet many purchasing managers still wrestle with recurring bottlenecks. Below are the four most‑frequent obstacles that erode margins and delay time‑to‑market.
1️⃣ Escalating Unit Costs
• Average price per gram of Liraglutide has risen **30 %** YoY due to limited suppliers.
• High freight tariffs on Asian shipments add another **$2‑3 / g**.
• Result: R&D budgets stretch thin, and product pricing becomes less competitive.
2️⃣ Inconsistent Purity & Bio‑activity
• Variability in peptide folding leads to ±15 % activity loss.
• Impurities such as host‑cell proteins trigger regulatory re‑jections.
• Result: Failed batch releases and costly re‑runs.
3️⃣ Lengthy Lead‑times & Unreliable Freight
• Traditional Asian manufacturers quote **6‑8 weeks** lead‑time, with a 20 % on‑time delivery risk.
• Port congestion and customs delays add **5‑10 days** extra.
• Result: Project timelines slip, affecting market launch windows.
4️⃣ Regulatory Uncertainty Across Borders
• Different jurisdictions demand distinct documentation (DMF, GMP, FDA‑approved batch records).
• Lack of a single source for compliant certificates forces duplicate testing.
• Result: Increased compliance costs and legal exposure.
Discover how Global Technology eliminates each of these pain points.
Solution Presentation – Global Technology’s Competitive Edge
Core Advantages (5‑point checklist)
- Powerful Factory Network: 3 GMP‑certified plants in China, each capable of 500 kg/year Liraglutide output.
- Quality Assurance: Full‑suite analytical profile (HPLC, MS, NMR) with ≥99.5 % purity and ≥98 % bio‑activity.
- OEM/ODM Design: Custom peptide sequences, lyophilized or solution forms, and label‑free or branded packaging.
- High‑Speed Delivery: 48‑hour free sample, 2‑week standard production, air‑freight from Zhengzhou to Los Angeles in 3 days.
- Transparent Pricing: FOB, CIF, and DDP options; volume‑based discounts start at 5 % for 10 kg orders.
Technical Specification Sheet
| Parameter | Value | Unit | Compliance |
|---|---|---|---|
| CAS Number | 820959‑17‑9 | — | All |
| Purity (HPLC) | ≥99.5 | % | USP, EP |
| Bio‑activity | ≥98 | % | FDA‑GLP‑1 assay |
| Form | Lyophilized powder / Sterile solution | — | ISO 9001, GMP |
| Stability | ≥24 months at –20 °C | — | ICH Q1A(R2) |
| Batch Size | 0.5 g – 500 kg | — | Customizable |
Application Scenarios & Case Studies
Case Study – Mid‑Size Biotech (2024): Replaced a legacy Asian supplier with Global Technology’s Liraglutide. Achieved 37 % cost reduction and cut lead‑time from 45 days to 14 days, enabling a Phase‑II launch 3 months ahead of schedule.
Case Study – Large Pharma (2025): Required GMP‑grade peptide for a combo GLP‑1/GLP‑2 trial. Our OEM service delivered 2 kg of lyophilized Liraglutide with a certificate of analysis (CoA) meeting both FDA and EMA expectations. The trial passed regulatory review on the first submission.
FAQ – All Procurement Queries Answered
What is the minimum order quantity (MOQ) for CAS 820959-17-9 Liraglutide?
Our standard MOQ is **0.5 g** for research‑grade material. For GMP‑grade bulk, the MOQ starts at **5 kg**. Custom batches below MOQ are possible with a surcharge.
Can you provide a Certificate of Analysis (CoA) that complies with FDA & EMA requirements?
Yes. Every batch is accompanied by a full CoA covering HPLC purity, MS identity, endotoxin level, residual solvents, and bio‑activity assay, all signed by our senior QA officer.
Do you offer OEM/ODM services for custom peptide sequences?
Absolutely. Our R&D team can synthesize, purify, and formulate any GLP‑1 analog up to 50 aa length, with lyophilized or sterile‑solution final forms.
What are the shipping options and typical transit times to the United States?
We provide **air‑freight (DDP)** (3‑5 days), **sea‑freight (CIF)** (15‑20 days), and **express courier (DPU)** for small samples (1‑2 days). All shipments are temperature‑controlled (2‑8 °C) with real‑time tracking.
How do you handle after‑sales support and possible batch failures?
Our technical support line operates 24/7. If a batch fails QC, we issue a **full replacement** within 48 h or provide a **money‑back guarantee**.
Secure Your Stock Before Prices Rise – Limited Quantity Available!
Risk‑Free Offer: Order today and receive a **free 100 mg sample** plus a **30‑day money‑back guarantee** if the purity does not meet the stated specifications.
Email Inquiry Now WhatsApp UsOffer valid until 30 days from today or until stock of 5 kg is exhausted – whichever comes first.
Customer Reviews – Voices from the Field
Maria L., Senior Procurement, BioGenix – "The batch we received had **99.7 % purity** and the documentation was flawless. Our FDA audit passed without a hitch."
David K., Operations Manager, MedPharm Solutions – "Delivery in 12 days instead of the quoted 30 saved us $12 k in storage fees. The free sample let us validate the assay before committing."
Linda S., C‑Level, Nova Therapeutics – "Their OEM capability allowed us to launch a novel GLP‑1 analog within 4 months – a timeline we thought impossible."
About the Author
Dr. Elena V. Morozova, Ph.D.
Senior Peptide Engineer with 15 years of experience in recombinant peptide production, GMP compliance, and cross‑border API logistics. Former Lead Scientist at a FDA‑approved biotech firm and current Technical Director at Global Technology Co., Ltd.
Published author of “Recombinant Peptide Manufacturing in the Era of GLP‑1 Therapies” (Journal of Pharmaceutical Innovation, 2024).
Contact: service@huanqiukeji9.com | Tel: +86 199 4383 0844
Global Technology Co., Ltd | No. 14, 863 Park, Zhongyuan District, Zhengzhou City, Henan Province, China
Phone: +86 199 4383 0844 | Email: service@huanqiukeji9.com
© 2026 Global Technology Co., Ltd – All Rights Reserved. Privacy Policy | Terms of Service
Social Proof – Trusted by Industry Leaders Worldwide
“Switching to Global Technology cut our Liraglutide cost by 28 % and delivery time by half. The purity data is rock‑solid – no surprises during FDA inspection.”
— John M., Procurement Director, NovoHealth Inc.
Certificates & Compliance (all up‑to‑date): CE, FDA, ISO 9001, GMP, DMF, HACCP, RoHS, CB, VDE, SAA, IPPC.